Cellectis S.A. (CLLS) Stock Forecast
Data as of Aug 8, 2026Healthcare · Current price $2.84 (+5.57%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
CLLS vs Sector & Market
| Metric | CLLS | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.00 | 2.25 | 2.42 |
| Analyst Count | 1 | 8 | 18 |
| Target Upside | +216.9% | +16286.2% | +14.7% |
| P/E Ratio | -5.94 | 3.59 | 36.06 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $15M | $15M | $15M | 2 |
| 2026-12-31 | $19M | $19M | $19M | 3 |
| 2027-03-31 | $38M | $38M | $38M | 3 |
| 2027-06-30 | $39M | $39M | $39M | 2 |
| 2027-09-30 | $103M | $103M | $103M | 2 |
| 2027-12-31 | $137M | $137M | $137M | 3 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $-0.25 | $-0.25 | $-0.25 | 1 |
| 2026-12-31 | $-0.22 | $-0.22 | $-0.22 | 1 |
| 2027-03-31 | $-0.47 | $-0.47 | $-0.47 | 1 |
| 2027-06-30 | $-0.49 | $-0.49 | $-0.49 | 1 |
| 2027-09-30 | $-0.08 | $-0.08 | $-0.08 | 1 |
| 2027-12-31 | $-0.03 | $-0.03 | $-0.03 | 1 |
Frequently Asked Questions
What is the analyst consensus for CLLS?
The consensus among 1 analysts covering Cellectis S.A. (CLLS) is Buy with an average price target of $9.00.
What is the highest price target for CLLS?
The highest analyst price target for CLLS is $9.00.
What is the lowest price target for CLLS?
The lowest analyst price target for CLLS is $9.00.
How many analysts cover CLLS?
1 analysts have issued ratings for Cellectis S.A. in the past 12 months.
Is CLLS a buy or sell right now?
Based on 1 analyst ratings, CLLS has a consensus rating of Buy (2.00/5) with a +216.9% upside to the consensus target of $9.00.
What are the earnings estimates for CLLS?
Analysts estimate CLLS will report EPS of $-0.25 for the period ending 2026-09-30, with revenue estimated at $15M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.